Myriad Says myPath Melanoma Test Highly Effective in Verification Study
Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that results from a verification study showed the Myriad myPath™ Melanoma test effectively differentiated malignant melanoma from benign skin lesions. The clinically-actionable information provided by myPath Melanoma will empower healthcare providers with objective data and improve the diagnosis of patients with melanoma. Myriad presented these data at the American Society of Dermatopathology Annual Meeting on Oct. 13, 2013.
The verification study evaluated a 23-gene panel designed to differentiate malignant melanoma from benign skin lesions. The study analyzed 464 skin biopsy samples including 254 samples representing melanomas from all major subtypes including superficial spreading, lentigo maligna melanoma, acral, nodular and desmoplastic lesions. Using this set of patient samples, the myPath Melanoma test demonstrated high sensitivity of 89 percent and specificity of 93 percent at differentiating malignant melanoma from benign skin lesions.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.